Connect Biopharma CEO Barry Quart said the rademikibart program continues to show a differentiated clinical and mechanistic profile, with mid-2026 data from the SEABREEZE study still pending. The update is supportive for the company’s long-term pipeline narrative but includes no new trial results or near-term catalyst. Market impact is likely limited unless upcoming data meaningfully changes the program outlook.
Connect Biopharma CEO Barry Quart said the rademikibart program continues to show a differentiated clinical and mechanistic profile, with mid-2026 data from the SEABREEZE study still pending. The update is supportive for the company’s long-term pipeline narrative but includes no new trial results or near-term catalyst. Market impact is likely limited unless upcoming data meaningfully changes the program outlook.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.12
Ticker Sentiment
